新城發展(01030.HK)8月合約銷售額按年跌13.9%
新城發展(01030.HK)公布,於2021年8月,實現合約銷售金額約177.39億元人民幣,按年跌13.9%;合約銷售面積約182.01萬平方米。首八個月累計合同銷售額約1,522.91億元,按年增長9.5%;累計銷售面積約1,424.36萬平方米。
另外,於8月,新城發展子公司通過合作方式取得廣東省廣州市白雲區鐘落潭福龍路東側地塊;廣西省南寧市編號為GC2021-013號地塊;江蘇省連雲港市編號為 LTC2007-65 號、LTC2007-66號及LTC2007-67號地塊;子公司又通過掛牌方式取得湖南省永州市零陵區香零山片區C-01-01號地塊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.